Sign In
Last checked at 
10 Mar 2010 11:00
ο»Ώ
Β
Β
Β
Hikma Pharmaceuticals PLC - Voting Rights and Capital
Β
LONDON, 10 March 2010 Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that as at 10 March 2010 its capital consists of 191,764,007 ordinary shares with voting rights. There are no shares held in treasury.
Β
The above figure (191,764,007) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and Transparency Rules.
Β
- ENDS -
Β
Enquiries:
Β
|
Hikma Pharmaceuticals PLC |
Β |
|
Henry Knowles Company Secretary Β |
+44 20 7399 2760 Β |
|
|
|
Β
Β
Β
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed pharmaceutical products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics". Hikma's operations are based principally in the Middle East and North Africa ("MENA") region, where it is a market leader and sells across 17 countries, the United States and Europe. In 2008, the Group achieved revenues of $580.7 million (2007 $449 million) and profit attributable to shareholders was $57.1 million (2007 $63 million). For news and other information, please visit www.hikma.com.
Β
Follow the stocks
